Gilead's Tecartus gets revised safety demand amid FDA's push for CAR-T boxed warnings
Fierce Pharma
JANUARY 24, 2024
Turns out, the FDA didn’t drop the CD19 CAR-T from a classwide safety alert list. . | The FDA’s letter demanding a labeling change for Gilead Sciences’ Tecartus temporarily went missing on the agency’s website Tuesday. Instead, it's adjusted the wording of a proposed boxed warning.
Let's personalize your content